Medicine and Dentistry
Biliary Atresia
100%
Pediatrics
91%
Liver Transplantation
58%
Liver Disease
51%
Chronic Hepatitis B
43%
Disease
41%
Liver Graft
38%
Hepatitis B Virus
34%
Hepatoportoenterostomy
32%
Infection
30%
Cholestasis
29%
Hepatitis C
29%
Hepatitis B
25%
Chronic Hepatitis C
25%
Bilirubin
25%
Hepatitis B(e) Antigen
23%
Liver Biopsy
23%
Alagille Syndrome
23%
Transplantation
20%
Biopsy
18%
Hepatocellular Carcinoma
18%
Quality of Life
17%
Fibrosis
15%
Acute Liver Failure
15%
Primary Sclerosing Cholangitis
13%
Hepatitis C Virus
13%
Placebo
13%
Breathing
13%
Alanine Aminotransferase
12%
Pediatrics Patient
12%
Peginterferon
12%
Prevalence
11%
Adolescent
10%
Neonatal Infant
10%
Recurrent Disease
10%
Portal Hypertension
10%
Ascites
9%
Biological Marker
9%
Cohort Effect
9%
Clinical Trial
9%
Retinol
9%
Antioxidant
9%
Alpha Tocopherol
8%
Antivirus Agent
8%
Health Care Cost
8%
Intrahepatic Cholestasis
8%
Lamivudine
8%
Virus Infection
8%
Cystic Fibrosis
8%
Ribavirin
8%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Hepatitis B
53%
Chronic Hepatitis C
51%
Infection
45%
Hepatitis B Virus
42%
Hepatitis C
42%
Ribavirin
38%
Hepatitis B
36%
Hepatitis B(e) Antigen
33%
Peginterferon
31%
Liver Disease
29%
Hepatitis C Virus
25%
Placebo
20%
Sofosbuvir
18%
Interferon
18%
Acute Liver Failure
18%
Liver Cell Carcinoma
16%
Liver Cirrhosis
16%
Alanine Aminotransferase
16%
Bile Duct Atresia
16%
Adverse Event
15%
Pharmacokinetics
15%
Lamivudine
15%
Disease
14%
Antivirus Agent
13%
Virus Infection
12%
Peginterferon Alpha2a
12%
Virus DNA
11%
Retinol
11%
Fibrosis
10%
Entecavir
10%
Alpha2a Interferon
10%
Peginterferon Alpha
10%
Alpha Tocopherol
10%
Biological Marker
9%
Clinical Trial
9%
Antioxidant
9%
Monotherapy
9%
Virus Hepatitis
9%
Bilirubin
8%
Hepatitis C Virus Genotype 2
8%
Chronic Hepatitis
8%
Hepatitis B Antigen
7%
Cystic Fibrosis
7%
Hepatitis E Virus
7%
Hepatitis C Virus Genotype 3
7%
Oxidizing Agent
7%
Alagille Syndrome
7%
Vancomycin
7%
Primary Sclerosing Cholangitis
7%
Combination Therapy
7%
Keyphrases
Biliary Atresia
48%
Chronic Hepatitis B
42%
Ribavirin
32%
Hepatitis B
32%
Chronic Hepatitis C
32%
Hepatitis B Virus
29%
Hepatitis C
27%
Hepatitis C Virus
25%
Hepatitis C Virus Infection
22%
Hepatitis B e Antigen (HBeAg)
21%
Hepatoportoenterostomy
20%
North America
19%
Pediatric
19%
Liver Transplantation
19%
United States
19%
Liver Biopsy
18%
Peginterferon
17%
Liver Disease
17%
Sofosbuvir
17%
Liver
15%
Cirrhosis
15%
Pegylated Interferon
15%
Pediatric Liver Transplant
14%
Infections in children
14%
Chronic Hepatitis B Virus Infection
14%
Chronic Hepatitis C Virus Infection
14%
Pediatric Liver Disease
13%
Pediatric Research
13%
Hepatitis B Surface Antigen (HBsAg)
13%
Pediatric Patients
12%
Canada
12%
Hepatocellular Carcinoma
12%
Hepatitis B Virus DNA
12%
Lamivudine
12%
Sustained Virological Response
11%
Ropeginterferon alfa-2b
11%
Fibrosis
11%
Virus
11%
Quality of Life
11%
Acute Liver Failure
11%
Ledipasvir
11%
Primary Sclerosing Cholangitis
11%
Clinical Trials
11%
Liver Transplant Recipients
10%
Health-related Quality of Life
10%
Total Bilirubin
10%
Placebo
10%
Hepatitis B Virus Infection
9%
Natural History
9%
Direct-acting Antivirals
9%